In short
PF-07976016-87 is an investigational oral medicine developed by Pfizer that has been studied in adults with obesity and overweight. It is a chemically synthesised substance given as a film-coated tablet. The clinical research programme includes one completed Phase 2 trial with 255 participants, which compared PF-07976016-87 against placebo on a background of liraglutide.
Key points
- PF-07976016-87 is an investigational oral medicine studied in adults with obesity and overweight.
- The only registered trial is a Phase 2 study with 255 participants, now completed.
- The trial compared multiple dose levels of PF-07976016-87 with placebo, on a background of liraglutide.
- The main measure was percent change in body weight from baseline at Week 16.
- PF-07976016-87 is given as a film-coated tablet by oral use.
- The substance has no marketing authorisation and remains investigational.
What is PF-07976016-87?
PF-07976016-87 is a chemical substance of synthetic origin, developed as an oral medicine for the treatment of obesity and overweight. It is classified in the registry under nutritional and metabolic diseases, which includes conditions such as obesity, as well as otorhinolaryngologic diseases. The substance is currently investigational, with no marketing authorisation in the product records. In the registered trial, PF-07976016-87 was given as a film-coated tablet for oral use.
How does PF-07976016-87 work?
The registry records do not describe the mechanism of action of PF-07976016-87. The trial data show that the substance was studied in combination with liraglutide, a medicine used for weight management, but the specific way in which PF-07976016-87 acts in the body is not stated in the available sources.
Which conditions is PF-07976016-87 studied for?
- Obesity — a condition of excess body fat that can affect health; the trial enrolled adults with obesity.
- Overweight — a body weight above what is considered healthy; the trial also included participants with overweight.
How is PF-07976016-87 given?
PF-07976016-87 is given by mouth as a film-coated tablet. The exact dose levels used in the trial were not reported in the registry record. The trial also included liraglutide as a background treatment, given by subcutaneous injection, and a placebo for PF-07976016-87 given orally.
What do the clinical trials show?
The clinical research programme for PF-07976016-87 consists of one completed Phase 2 trial with 255 participants. The trial compared the effect of multiple dose levels of PF-07976016-87 versus placebo on body weight in participants with obesity, on a background of liraglutide. The primary measure was the percent change from baseline in body weight at Week 16. The trial is registered in the EU Clinical Trials Information System under the number 2024-513679-42-00.
What side effects are known?
The registry record for the completed Phase 2 trial does not report side effects for PF-07976016-87. No supplementary sources describing the safety profile of the substance were provided.